Tuesdays 17th & 24th November and 1st December 2026
3pm GMT | 4pm CET | 10am ET
Liquid biopsy has enormous potential to transform cancer diagnosis, monitoring and treatment, but realising this potential requires more than increasingly sensitive technologies. Different cancers, patient populations and clinical applications present distinct challenges, from identifying the most informative biomarkers to recovering tumour-derived signals from limited samples and demonstrating clinical utility.
Across the series, you will learn how to:
- Choose the right approach: Understand how cancer type, disease stage and patient population influence biomarker, biofluid and assay selection, including the distinct challenges of paediatric cancers.
- Push the limits of detection: Explore how researchers are improving sample processing, enrichment and analysis to recover meaningful cancer signals from limited samples.
- Bridge the gap to clinical impact: Discover how biomarker validation, multimodal approaches and evidence of clinical utility are helping move liquid biopsy towards routine cancer care.
Webinar 1: Right Test, Right Patient
Tuesday 17th November 2026 at 3pm GMT | 4pm CET | 10am EST
Sponsored by Thermo Fisher Scientific
There is no single ‘best’ approach to liquid biopsy. So how do we identify the right tests and biomarkers for different patients?
From molecular characterisation of paediatric cancers to the potential of cerebrospinal fluid (CSF) liquid biopsy for brain tumours where tissue sampling can be difficult or high-risk, this webinar will explore how researchers are adapting diagnostic strategies to different clinical challenges.
Discover how cancer type, disease stage and patient population influence the choice of biomarkers, biofluids and assays, and what challenges remain in translating these approaches into clinical practice.
Talk 1: The Evolving Landscape of Liquid Biopsy in Oncology
Catherine Alix-Panabières, Professor of Oncology and Director of the Laboratory of Rare Human Circulating Cells, University of Montpellier
Talk 2: Review of the NCI/COG’s Molecular Characterization Initiative for Paediatric Solid Tumours
Yassmine Akkari, Senior Director, Institute for Genomic Medicine, Nationwide Children’s Hospital
Talk 3: The Clinical Potential of CSF Liquid Biopsy in Paediatric Brain Tumours
Liana Nobre, Assistant Professor, University of Alberta
Webinar 2: Finding the Signal: Overcoming the Limits of Liquid Biopsy Detection
Tuesday 24th November 2026 at 3pm GMT | 4pm CET | 10am EST
Sponsored by Twist Bioscience
What happens when the cancer signal you’re looking for is barely detectable?
In applications such as minimal residual disease monitoring and early cancer detection, tumour-derived material can be extraordinarily scarce. Improving detection isn’t simply a question of sequencing deeper: where circulating tumour DNA is found, how samples are processed and how signals are enriched can all influence what researchers can detect.
This webinar will explore how researchers are addressing the biological and technical barriers to liquid biopsy detection. Discover advances in sample processing, tumour signal enrichment and cfDNA analysis that could help recover more meaningful information from limited samples and improve the sensitivity and reliability of liquid biopsy assays.
Talk 1: Where, When and How to Capture Circulating Tumour DNA
Daniel Hagey, Assistant Professor, Karolinska Institutet
Talk 2: Capturing the Signal with Tumor-Informed MRD Panels
Hanna Berning, Staff Product Marketing, NGS, Twist Bioscience
Talk 3: Overcoming the Molecular Limits of cfDNA Detection
Shervin Tabrizi, Assistant Professor of Radiation Oncology, University of Pennsylvania
Webinar 3: From Promising Assay to Real-World Impact
Tuesday 1st December 2026 at 3pm GMT | 4pm CET | 10am EST
A promising biomarker is only the beginning. What does it take to turn a scientific discovery into a clinically useful test?
Liquid biopsy research continues to uncover promising biomarkers and new opportunities for cancer detection and monitoring. But demonstrating analytical performance is only one part of the challenge. Clinical validation, evidence of patient benefit and practical implementation are all essential to translating these advances into routine care.
This webinar will explore how researchers are bridging the gap between biomarker discovery and clinical application. From DNA methylation biomarkers to approaches combining multiple molecular signals, discover how researchers are evaluating clinical utility, improving diagnostic performance and addressing the challenges of bringing liquid biopsy into real-world practice.
Talk 1: From Tumour Biology to Clinical Decisions: The Evolving Role of Liquid Biopsy
Klaus Pantel, Director of the Institute of Tumour Biology, University Medical Center Hamburg-Eppendorf
Talk 2: Demonstrating Clinical Utility: Lessons from DNA Methylation Biomarkers
Guro Elisabeth Lind, Professor of Epigenetics, Oslo University Hospital
Talk 3: Integrating Multiple Biomarkers to Improve Liquid Biopsy Performance
Dominic Rothwell, Deputy Director, CRUK National Biomarker Centre
Register for Cancer Diagnostics ONLINE – Turning Data into Decisions Tuesdays 17th & 24th November and 1st December 2026 , 3pm GMT | 4pm CET | 10am ET
